VOR VS ALT Stock Comparison

Performance

VOR
10/100

VOR returned -61.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

ALT
10/100

ALT returned -81.64% in the last 12 months. Based on SPY's performance of -21.23%, its performance is below average giving it a score of 10 of 100.

Technicals

VOR
10/100

VOR receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

ALT
14/100

ALT receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

Earnings

VOR
10/100

VOR has missed earnings 6 times in the last 20 quarters.

ALT
60/100

ALT has missed earnings 3 times in the last 20 quarters.

Profit

VOR
10/100

Out of the last 16 quarters, VOR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

ALT
10/100

Out of the last 20 quarters, ALT has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

VOR
43/100

VOR has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

ALT
43/100

ALT has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

Analyst Price Targets

VOR

"Analyst Price Targets" not found for VOR

ALT
75/100

1 analysts offer 12-month price targets for ALT. Together, they have an average target of 31.2, the most optimistic target put ALT at 50 within 12-months and the most pessimistic has ALT at 20.

Sentiment

VOR

"Sentiment" not found for VOR

ALT
68/100

ALT had a bullish sentiment score of 68.47% across Twitter and StockTwits over the last 12 months. It had an average of 390.95 posts, 614,471.08 comments, and 647,677.88 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Vor Biopharma Inc. Common Stock Summary

Nasdaq / VOR

Healthcare

Biotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Altimmune, Inc. Common Stock Summary

Nasdaq / ALT

Healthcare

Biotechnology

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Power up your portfolio